跳至主要内容
临床试验/NCT00586378
NCT00586378已完成3 期

Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study

ELA Medical, Inc.2 个研究点 分布在 1 个国家目标入组 85 人开始时间: 2006年4月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
85
试验地点
2
主要终点
Shock effectiveness for VT/VF

研究概览

简要总结

The purpose of this post-approval study is to confirm the safety and effectiveness of Ovatio DR and VR ICDs

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Candidates will come from the investigator's general ICD population who meet any of the accepted indications for an ICD implant according to the "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death" (Zipes et al., JACC Vol. 48, No. 5, Sept. 2006:1064-1108).

排除标准

  • Ventricular tachyarrhythmia that may have transient or reversible causes such as: acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia, sepsis, or unstable ischemic episodes
  • Incessant tachyarrhythmia
  • Implanted pacemaker
  • Primary disorder of bradyarrhythmia or atrial tachyarrhythmia
  • Of minor age
  • Participating in another clinical study

结局指标

主要结局

Shock effectiveness for VT/VF

时间窗: 6 months

The percentage of patients free from complications

时间窗: 6 months

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Ovatio DR and VR Implantable Cardioverter... | 临床试验